View Exam | PowerPak

1. Which of the following is true regarding HER2+ breast cancer?

A. It is the most common form of breast cancer B. It is distinct and does not overlap with HR+ disease C. It makes up 20% of all breast cancer cases D. Brain metastases is uncommon

2. LG is a 38-year-old female who presents to the clinic with a new right breast mass. CT evidence of 4 small hepatic lesions consistent with metastasis. Immunohistochemistry is positive for HER2/neu amplification (3+). What therapy regimen do you recommend for LG?

A. Docetaxel + carboplatin + trastuzumab + pertuzumab (TCHP) B. Trastuzumab + pertuzumab + docetaxel C. Ado-trastuzumab emtansine (T-DM1) D. Fam-trastuzumab deruxtecan (DS 8201)

3. What second-line treatment would you recommend for a metastatic breast cancer patient who progressed on trastuzumab and paclitaxel?

A. Capecitabine + lapatinib B. Neratinib + vinorelbine C. Ado-trastuzumab emtansine (T-DM1) D. Fam-trastuzumab deruxtecan (DS 8201)

4. What toxicity prevention and monitoring is recommended while on trastuzumab deruxtecan?

A. Antiemetics—5HT3 RA + steroid B. CBC w/ differential prior to each dose C. LVEF at baseline and regularly D. Monitor for cough, dyspnea, fever, or new or worsening pulmonary symptoms E. All the above

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is true regarding HER2+ breast cancer?

2. LG is a 38-year-old female who presents to the clinic with a new right breast mass. CT evidence of 4 small hepatic lesions consistent with metastasis. Immunohistochemistry is positive for HER2/neu amplification (3+). What therapy regimen do you recommend for LG?

3. What second-line treatment would you recommend for a metastatic breast cancer patient who progressed on trastuzumab and paclitaxel?

4. What toxicity prevention and monitoring is recommended while on trastuzumab deruxtecan?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is true regarding HER2+ breast cancer?

2. LG is a 38-year-old female who presents to the clinic with a new right breast mass. CT evidence of 4 small hepatic lesions consistent with metastasis. Immunohistochemistry is positive for HER2/neu amplification (3+). What therapy regimen do you recommend for LG?

3. What second-line treatment would you recommend for a metastatic breast cancer patient who progressed on trastuzumab and paclitaxel?

4. What toxicity prevention and monitoring is recommended while on trastuzumab deruxtecan?

« Return to Activity

Customers who Purchased
this Activity also Purchased